Abstract:Objective:In order to test for the presence of a circulating factor(CF),an in vitro method for quantifying glomerular permeability in rats was utilized.In this study,we utilized podocytes to determine the presence of CF and explore the mechanism by which it overcomes the glomerular permeability barrier.Methodology:Eighty sera from patients with FSGS and Seventy from patients with podocytopathy were investigated.Sera from nephrotic syndrome patients with MN,IgMN,IgAN,DN,LN or MPGN were also studied as controls.Differentiated podocytes were treated with 1ml of medium containing 10% vol/vol of serum from patients for 24hrs.Changes in both F-actin and ZO-1 patterns in podocytes were observed by confocal microscopy.At the same time,Sprague-Dawley rats were injected with 0.1 ml serum from above patients.The level of urine protein in the rats were determined at 0h,4h,8h,12h and 24h.To characterize the nature of CF,the sera were processed before treated podocytes as decomplement,removed lipoproteins by dextran sulfate and calcium chloride,removed IgG by 70%(NH4)2SO4 saturation,pre-incubated with the homologous nephrotic urine or normal sera,or neutralized with IL-13 antibody.In order to understand the underlying effect of CF on podocytes,the activity of JAK-STAT 6,MAPK and RhoA signal pathways were studied using western blot.Results:CF presented in 16.3% of FSGS and 12.2% of podocytopathy patients by using podocytes as a target cell,while CF was not detected in other nephrotic patients(IgAN,MN,MPGN,LN,DN).Sera from certain patients with FSGS and podocytopathy destroyed the cytoskeleton of podocyte,as well as damaged the tight junction of podocyte.Injection of the sera which damaged podocyte induced proteinuria in rats as fast as 8h(0.5±0.03 mg/ml vs 0.2±0.01 mg/ml control sera,P<0.01),and as peak as 12h.Although decomplement,precipitated at 70% ammonium sulfate and removed lipoproteins,the positive sera still contained the CF activity.Activate the cellular signal transduction pathways(RhoA,STAT and p38 MAPK).Coincubation of serum with homologous urine and normal serum could not neutralize the activation of CF,it did not support the missing factor hypothesis.In addition,IL-13 neutralizing antibody did not affect the bioactivity of CF.Proteins from podocytes injuried by sera from patients with FSGS and podocytopathy showed activation of STAT6,p-38 MAPK and RhoA signal pathways as early as 30 min.Conclusion:Ciculating factor,which was specificity presence in patients with FSGS and podocytopathy,directly acted on podocytes and disrupt cytoskeleton as well as cell-cell interation.Multiple signal pathways could be involved in the effect of CF on podocytes.Our study provides new insights into the pathogenesis of FSGS,thus potentially contributing to the design of individual therapeutic strategies in FSGS.

Colony stimulating factor-1 receptor drives glomerular parietal epithelial cell activation in focal segmental glomerulosclerosis

Endothelial Mitochondrial Oxidative Stress Determines Podocyte Depletion in Segmental Glomerulosclerosis.

Blocking Ribosomal Protein S6 Phosphorylation Inhibits Podocyte Hypertrophy and Focal Segmental Glomerulosclerosis.

Protective role of the podocyte IL-15 / STAT5 pathway in focal and segmental glomerulosclerosis

Visualize circulating factor by using podocytes as a taget cell in patients with FSGS

Application to Focal and Segmental Glomerulosclerosis

C3a and Supar Drive Versican V1 Expression in Tubular Cells of Focal Segmental Glomerulosclerosis

Gain-of-function mutations in transient receptor potential C6 (TRPC6) activate extracellular signal-regulated kinases 1/2 (ERK1/2)

Btg2 Promotes Focal Segmental Glomerulosclerosis via Smad3‐Dependent Podocyte‐Mesenchymal Transition

Bioinformatic Analysis Combined With Experimental Validation Reveals Novel Hub Genes and Pathways Associated With Focal Segmental Glomerulosclerosis

Parietal epithelial cells differentiate into podocytes dependent on ROS-Nrf2-Brg1 signaling

Renal Glomerular Expression of WT-1, TGF-β, VEGF, and ET-1 Immunostains in Murine Models of Focal and Segmental Glomerulosclerosis

Podocyte repopulation by renal progenitor cells following glucocorticoids treatment in experimental FSGS.

The long noncoding RNA LOC105374325 causes podocyte injury in individuals with focal segmental glomerulosclerosis.

Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis

The role of the FSGS disease gene product and nuclear pore protein NUP205 in regulating nuclear localization and activity of transcriptional regulators YAP and TAZ

Urinary Soluble Urokinase Receptor Levels Are Elevated and Pathogenic in Patients with Primary Focal Segmental Glomerulosclerosis

A Rare Autosomal Dominant Variant in Regulator of Calcineurin Type 1 ( RCAN1 ) Gene Confers Enhanced Calcineurin Activity and May Cause FSGS

Fibrinogen Links Podocyte Injury with Toll-like Receptor 4 and is Associated with Disease Activity in FSGS Patients.

Novel diagnostic and therapeutic techniques reveal changed metabolic profiles in recurrent focal segmental glomerulosclerosis

Podocyte YAP ablation decreases podocyte adhesion and exacerbates FSGS progression through α3β1 integrin